Zoetis (NYSE:ZTS) Given New $141.00 Price Target at UBS Group

Zoetis (NYSE:ZTS) had its price target cut by UBS Group from $158.00 to $141.00 in a research note published on Wednesday,Benzinga reports. They currently have a neutral rating on the stock.

ZTS has been the subject of several other research reports. JPMorgan Chase & Co. lowered their target price on Zoetis from $230.00 to $200.00 and set an “overweight” rating for the company in a research note on Wednesday. Weiss Ratings reiterated a “hold (c-)” rating on shares of Zoetis in a research report on Wednesday, October 8th. Argus restated a “buy” rating and issued a $190.00 target price on shares of Zoetis in a research report on Tuesday, September 9th. Leerink Partnrs cut shares of Zoetis from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 17th. Finally, Stifel Nicolaus set a $140.00 price target on Zoetis in a research note on Tuesday. Five research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $191.00.

Zoetis Price Performance

NYSE:ZTS opened at $120.47 on Wednesday. Zoetis has a 12-month low of $119.07 and a 12-month high of $181.85. The firm has a market capitalization of $53.39 billion, a price-to-earnings ratio of 20.73, a P/E/G ratio of 2.31 and a beta of 0.90. The stock’s 50 day moving average price is $145.63 and its two-hundred day moving average price is $153.01. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05.

Zoetis (NYSE:ZTS) last posted its earnings results on Tuesday, November 4th. The company reported $1.70 earnings per share for the quarter, topping analysts’ consensus estimates of $1.62 by $0.08. The company had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.42 billion. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The company’s revenue was up .5% on a year-over-year basis. During the same quarter last year, the firm earned $1.58 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, analysts anticipate that Zoetis will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 2nd. Investors of record on Friday, October 31st will be issued a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.7%. The ex-dividend date is Friday, October 31st. Zoetis’s dividend payout ratio (DPR) is currently 34.42%.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the stock. AdvisorShares Investments LLC boosted its position in shares of Zoetis by 12.8% during the 3rd quarter. AdvisorShares Investments LLC now owns 3,165 shares of the company’s stock worth $463,000 after purchasing an additional 360 shares in the last quarter. German American Bancorp Inc. increased its position in Zoetis by 2.3% in the 3rd quarter. German American Bancorp Inc. now owns 21,815 shares of the company’s stock valued at $3,192,000 after buying an additional 490 shares in the last quarter. Diamond Hill Capital Management Inc. acquired a new position in shares of Zoetis during the third quarter worth approximately $394,010,000. Plato Investment Management Ltd grew its position in Zoetis by 22.9% in the 3rd quarter. Plato Investment Management Ltd now owns 15,449 shares of the company’s stock valued at $2,243,000 after purchasing an additional 2,874 shares during the period. Finally, Correct Capital Wealth Management increased its stake in Zoetis by 100.3% during the 3rd quarter. Correct Capital Wealth Management now owns 14,705 shares of the company’s stock valued at $2,152,000 after purchasing an additional 7,365 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.